Zandelisib Displays “Exemplary” Efficacy in Relapsed/Refractory Follicular Lymphoma
Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.
Diagnosis & Disease Information
Tisagenlecleucel Demonstrates Activity in Young Patients With R/R Non-Hodgkin Lymphoma
Tisagenlecleucel can produce responses in children and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma, a phase 2 study suggests.
Predicting Disease Progression in Patients With MALT Lymphoma
The researchers examined the prognostic significance of AMC and LMR in 316 patients with MALT lymphoma.
Obinutuzumab Bests Rituximab in Previously Untreated Follicular Lymphoma
Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.
Blinatumomab Linked to Higher Costs, Hospitalizations for R/R ALL
The mean total cost of care was $65,437 for blinatumomab, $55,995 for inotuzumab, and $17,520 for other agents.
Convalescent or Vaccinated-Donor Plasma Improves COVID-19 Outcomes in Immunosuppressed Patients
Researchers sought to determine whether using convalescent plasma or plasma from vaccinated donors could improve COVID-19 in patients with a hematologic malignancy or immunosuppression.
Guidelines for CML Not Followed in the Real World
“Excellent” overall survival is achievable with currently available drugs, according to researchers.
Thalidomide Vs Lenalidomide for Newly Diagnosed Multiple Myeloma
Researchers sought to compare thalidomide with lenalidomide in patients with transplant-ineligible newly diagnosed multiple myeloma.
Long-Term Analysis of SCT800 in Patients With Severe Hemophilia A
Researchers sought to assess SCT800 in patients with severe hemophilia A.
Orelabrutinib-Sintilimab Yields Responses in Primary CNS Lymphoma
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...